2023-07-27
On July 27, 2023, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") first self-developed product "atomoxetine hydrochloride oral solution (trade name: 贝择思®)” has been successfully approved by the Chinese CDE for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 years...
More +2023-07-10
Recently, the three-day CPHI&PMEC China 2023were held atthe Shanghai New International Expo Center. Hetero Labs Limited, the premiumpartner of Shenzhen Beimei Pharmaceutical Co., Ltd.,participated inthe exhibition and awarded Beimei Pharmaceutical The Most Valuable PartnerCollaboration Award.(BeiMei Pharma's Chairman and CEO, Claire Wu, receives the ...
2023-07-10
Recently, the three-day CPHI&PMEC China 2023were held atthe Shanghai New International Expo Center. Hetero Labs Limited, the premiumpartner of Shenzhen Beimei Pharmaceutical Co., Ltd.,participated inthe exhibition and awarded Beimei Pharmaceutical The Most Valuable PartnerCollaboration Award.(BeiMei Pharma's Chairman and CEO, Claire Wu, receives the ...
2023-06-27
June 25, 2023, the production base of Beimei Pharma (a wholly-owned subsidiary of Beimei Pharmaceutical—Jiangsu Beimei Pharmaceutical Co., Ltd.) successfully settled in the International Pharmaceutical Innovation Industrial Park of Lianyungang Free Trade Zone. The attendees inthe ceremony were: JiajiongZhang, Deputy Mayor of Lianyungang City,YuanYin, Deputy Director ...
2023-06-27
June 25, 2023, the production base of Beimei Pharma (a wholly-owned subsidiary of Beimei Pharmaceutical—Jiangsu Beimei Pharmaceutical Co., Ltd.) successfully settled in the International Pharmaceutical Innovation Industrial Park of Lianyungang Free Trade Zone. The attendees inthe ceremony were: JiajiongZhang, Deputy Mayor of Lianyungang City,YuanYin, Deputy Director ...
2023-06-07
After the applicationof procaterol hydrochloride oral solution was accepted on May 29, 2023, our company had another good news again this week. On June 6, 2023, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") has officially received the acceptance letter issued by the Drug Evaluation Center of the National Medical Products ...
2023-06-07
After the applicationof procaterol hydrochloride oral solution was accepted on May 29, 2023, our company had another good news again this week. On June 6, 2023, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") has officially received the acceptance letter issued by the Drug Evaluation Center of the National Medical Products ...
2023-05-29
On May 29, 2023, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") has officially received the acceptance letter issued by the Drug Evaluation Center of the National Medical Products Administration. The procaterol hydrochloride oral solution, which isindependently developed by Beimei Pharmaceutical,its application was accep...
2023-05-29
On May 29, 2023, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") has officially received the acceptance letter issued by the Drug Evaluation Center of the National Medical Products Administration. The procaterol hydrochloride oral solution, which isindependently developed by Beimei Pharmaceutical,its application was accep...
2023-03-22
A few days ago, Shenzhen Small and medium-sized Enterprise Service Bureau released the "Shenzhen Small and Medium-sized Enterprise Service Bureau- the list of Shenzhen SRDI small and medium-sized enterprises in 2022", after enterprise declaration, expert review and other aspects, with the outstanding performance of children medicine field, Shenzhen Beimei Pharmaceutic...
2023-03-22
A few days ago, Shenzhen Small and medium-sized Enterprise Service Bureau released the "Shenzhen Small and Medium-sized Enterprise Service Bureau- the list of Shenzhen SRDI small and medium-sized enterprises in 2022", after enterprise declaration, expert review and other aspects, with the outstanding performance of children medicine field, Shenzhen Beimei Pharmaceutic...
2023-03-09
February 28, 2023, Three doses (10 mg, 20 mg, 40 mg) ofEsomeprazole magnesium for delayed release oral suspension（卫艾宁®）, the imported finished product which islicensed fromCipla Ltd. , were formally approved by the NMPA, the National Medical Products Administration. It is approved for the treatment of gastroesophageal reflux disease, eradication of Helicobacter pylori in combi...
2023-03-09
February 28, 2023, Three doses (10 mg, 20 mg, 40 mg) ofEsomeprazole magnesium for delayed release oral suspension（卫艾宁®）, the imported finished product which islicensed fromCipla Ltd. , were formally approved by the NMPA, the National Medical Products Administration. It is approved for the treatment of gastroesophageal reflux disease, eradication of Helicobacter pylori in combi...
2023-02-10
On February 03, 2023, Shenzhen BeimeiPharmaceutical Co., Ltd (hereinafter referred to as "BeimeiPharmaceutical") received the Acceptance Notice issued by the State Drug Administration of China (SDA), and the application for marketing authorization for the production of DesloratadineOral Solution within the Company's territory was accepted.DesloratadineOral So...
2023-02-10
On February 03, 2023, Shenzhen BeimeiPharmaceutical Co., Ltd (hereinafter referred to as "BeimeiPharmaceutical") received the Acceptance Notice issued by the State Drug Administration of China (SDA), and the application for marketing authorization for the production of DesloratadineOral Solution within the Company's territory was accepted.DesloratadineOral So...
2022-12-26
On December 26, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Syrimed reached an exclusive license and supply agreement of a skeletal muscle relaxation oral solution product (hereinafter referred to as "the product"). Under the terms of the agreement, Beimei will be responsible for the registration and commer...
2022-12-26
On December 26, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Syrimed reached an exclusive license and supply agreement of a skeletal muscle relaxation oral solution product (hereinafter referred to as "the product"). Under the terms of the agreement, Beimei will be responsible for the registration and commer...
2022-12-02
On December 2, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Cipla Ltd. (hereinafter referred to as " Cipla ") reached an exclusive license and supply agreement of a neonatal pharmaceutical product (hereinafter referred to as "the product"). Under the terms of the agreement, Beimei will be respons...
2022-12-02
On December 2, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Cipla Ltd. (hereinafter referred to as " Cipla ") reached an exclusive license and supply agreement of a neonatal pharmaceutical product (hereinafter referred to as "the product"). Under the terms of the agreement, Beimei will be respons...
